New insights on ocular surface disease in atopic dermatitis patients treated with dupilumab

Br J Dermatol. 2021 Aug 25. doi: 10.1111/bjd.20706. Online ahead of print.ABSTRACTDupilumab was approved by the Food and Drug Administration and European Medicine Agency in 2017 for use in adults with moderate-to-severe atopic dermatitis (AD) [1]. One of the most commonly reported adverse events of dupilumab is ocular surface disease, initially termed "conjunctivitis" in clinical trials [2]. A more appropriate definition is dupilumab-induced ocular surface disease (DIOSD), first proposed by Zirwas [3]. Typical symptoms of DIOSD include tearing, foreign body sensation, burning sensation, itching and photophobia [1-3]. Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. We included in the study 25 patients who underwent ophthalmological evaluation at baseline (t0) and after 4 months of dupilumab treatment (t1). In the context of ocular assessment, all patients completed the Ocular Surface Disease Index (OSDI) questionnaire, a standardized evaluation scale of dry eye-related symptoms [4]. Seven subjects of our cohort (28%) had a past history of conjunctivitis, in line with the reported prevalence of keratoconjunctivitis in AD patients [5]. Patients treated with dupilumab were compared at t0 and t1 to a non-atopic control group composed by 25 subjects.PMID:34431510 | DOI:10.1111/bjd.20706

Source: The British Journal of Dermatology - August 25, 2021 Category: Dermatology Authors: P Bortoluzzi S Ferrucci D Galimberti F Garavelli F Pozzo Giuffrida A Pizzati A V Marzano C Mapelli Source Type: research